Important Safety Information
DepoDur is not intended for intrathecal, intravenous, or intramuscular administration. Administration into the thoracic epidural space or higher has not been evaluated and therefore is not recommended. Ther majority of adverse events were typical opioid-related side effects and would be expected in the surgical populations studied. No statistically significant differences between treatment groups with respect to nausea, pruritus, sedation scores, vomiting episodes, or urinary retention.

References:

1. 1. Viscusi ER, Martin G, Hartrick CT, Singla N, Manvelian G; for the EREM Study Group. Forty-eight hours of postoperative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulation. Anesthesiology. 2005;102(5):1014-1022.
2. 2. Hartrick CT, Martin G, Kantor G, Koncelik J, Manvelian G. Evaluation of a single-dose, extended-release epidural morphine formulation for pain after knee arthroplasty. J Bone Joint Surg Am. 2006;88(2):273-281.
3. 3. Gambling D, Hughes T, Martin G, Horton W, Manvelian G; for Single-Dose EREM Study Group. A comparison of DepoDur, a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. Anesth Analg. 2005;100(4):1065-1074.
4. 4. Carvalho B, Roland LM, Chu LF, Campitelli VA III, Riley ET. Single-dose, extended-release epidural morphine (DepoDur) compared to conventional epidural morphine for post-Cesarean pain. Anesth Analg. 2007;105(1):176-183.
5. 5. Howell SB. Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology. Cancer J. 2001;7(3):219-227.
6. 6. Data on file, EKR Therapeutics, Inc.